{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:26Z","timestamp":1792813226835,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,4,25]],"date-time":"2005-04-25T00:00:00Z","timestamp":1114387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> The spectrum of CD30\u2010positive cutaneous lymphoproliferative disorders (CD30<jats:sup>+<\/jats:sup> CLPD) includes lymphomatoid papulosis (LyP), primary cutaneous CD30<jats:sup>+<\/jats:sup> large T\u2010cell lymphoma (LTCL) and rare borderline patients. Despite their malignant histopathology, CD30<jats:sup>+<\/jats:sup> CLPD exhibit a low\u2010grade malignant course with an excellent prognosis and a characteristic tendency for spontaneous regression. Apoptosis of tumour cells is considered a principal mechanism of tumour regression. We examined the proliferation and apoptosis rates as well as the expression of apoptosis\u2010related proteins in various clinical entities, tumour cell lines and evolutional (evolving and regressing) stages of CD30<jats:sup>+<\/jats:sup> CLPD. Skin biopsies of LyP (<jats:italic>n<\/jats:italic>\u2003=\u200320) and LTCL (<jats:italic>n<\/jats:italic>\u2003=\u200319) and five CD30<jats:sup>+<\/jats:sup> lymphoma cell lines were analysed by means of immunohistochemistry and Western blotting in order to evaluate the proliferation (Ki67), apoptosis (FragEl) and expression of Bax, Bcl\u2010x, C\u2010kit and Mcl\u20101. A significantly higher apoptotic index (AI) was found in LyP (AI\u2003=\u200312.5%) than in LTCL (AI\u2003=\u20033.1%, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.005). Bax was expressed by the majority of tumour cells in all forms of CD30<jats:sup>+<\/jats:sup> CLPD and CD30<jats:sup>+<\/jats:sup> cell lines. However, no Bax expression was found in tumour cell lines derived from systemic CD30<jats:sup>+<\/jats:sup> lymphomas, which lack spontaneous regression and display an aggressive clinical course. No significant correlation was found between the expression of apoptosis\u2010related proteins and the tumour type and evolutional stage of CD30<jats:sup>+<\/jats:sup> CLPD. We conclude that the higher AI in LyP may contribute to the regression of LyP lesions and the excellent prognosis of the disease. Pro\u2010apoptotic protein Bax is expressed at high levels in CD30<jats:sup>+<\/jats:sup> CLPD and may play a crucial role in mediating apoptosis of tumour cells.<\/jats:p>","DOI":"10.1111\/j.0906-6705.2005.00293.x","type":"journal-article","created":{"date-parts":[[2005,4,25]],"date-time":"2005-04-25T12:57:49Z","timestamp":1114433869000},"page":"380-385","source":"Crossref","is-referenced-by-count":19,"title":["Apoptosis in CD30\u2010positive lymphoproliferative disorders of the skin"],"prefix":"10.1111","volume":"14","author":[{"given":"Johannes","family":"Greisser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Doebbeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirka","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall E.","family":"Kadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1993.tb02734.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1994.tb00549.x"},{"key":"e_1_2_6_4_2","first-page":"315","article-title":"Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease\u2010associated antigens","volume":"119","author":"Kadin M","year":"1985","journal-title":"Am J Pathol"},{"key":"e_1_2_6_5_2","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze R","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.97.1.23"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930315)71:6<2097::AID-CNCR2820710626>3.0.CO;2-7"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.3653"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.133.7.829"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V94.9.3077","article-title":"CD30\u2013CD30 ligand interaction in primary cutaneous CD30 (+) T\u2010cell lymphomas: a clue to the pathophysiology of clinical regression","volume":"94","author":"Mori M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04523.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1997.tb01319.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90249-0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1242\/dev.120.10.3033"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1200927"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2470.bloodjournal8762470"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054813"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006626200"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.v5.i2-3.30"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.3.785.785"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.8.2854.420k07_2854_2861"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64073-4"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.1.234.234"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/32.2.6198355"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200106000-00082"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)02643-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-198100320-00004"},{"key":"e_1_2_6_28_2","first-page":"3867","article-title":"TGF beta 1 kills lymphoma cells using mitochondrial apoptotic pathway with the help of caspase\u20108","volume":"22","author":"Barna G","year":"2002","journal-title":"Anticancer Res"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj\/leu\/2401415"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5493.989"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.8.3173"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90451-8"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000030005"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1341"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.423958.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1997.tb00955.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004010050860"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03471.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008384631177"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0906-6705.2005.00293.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0906-6705.2005.00293.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:43:49Z","timestamp":1695815029000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0906-6705.2005.00293.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,25]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.0906-6705.2005.00293.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0906-6705.2005.00293.x","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,25]]}}}